

Retatrutide 60 mg

RT-2026-049 Lot PAL-RET60-2069-60 Analyzed October 30, 2026



TIMELINE	SAMPLE	TESTING
ORDERED	NAME	CLIENT
October 24, 2026	Retatrutide 60 mg	Egma
RECEIVED	EXPECTED	TEST TYPE
October 29, 2026	Retatrutide	Content & purity
ANALYZED	AMOUNT	METHOD
October 30, 2026	1 vial, lyophilized powder	HPLC-UV

CONTENT, HOW MUCH IS IN IT

Not detected

Label claim: 60 mg


IDENTITY, WHAT IT IS

Not detected

No retatrutide detected

CHROMATOGRAM

HPLC-UV



● 3.72 min, Unidentified component --- Retatrutide reference, same method

ANALYST COMMENTS

White lyophilized powder, black-cap vial, received sealed. Retatrutide was not found in the sample (detection limit about 0.2 mg per vial). The dashed trace is a retatrutide reference run on the same method, marking where retatrutide elutes. The only significant peak is an early eluting unidentified UV-absorbing component at 3.72 minutes.

ANALYST SIGNATURE

Max Barrett
Lab Director, PuriLab Analytical
Analysis date: October 30, 2026

VERIFICATION CODE

RT-EUZ6-I5HQ
Verify at purilab.org/verify/RT-EUZ6-I5HQ

SCAN TO VERIFY



RT-EUZ6-I5HQ

Results apply solely to the sample as received and are not representative of any larger lot, batch, or production run. Findings are limited to the analytes stated above. PuriLab Analytical is an independent testing laboratory, is not CLIA certified or ISO 17025 accredited, does not sell or distribute any substance, and makes no representation as to the safety, legality, or fitness of any material for any use.